Avanos Medical (NYSE:AVNS) Rating Lowered to “Hold” at Wall Street Zen

Avanos Medical (NYSE:AVNS) was downgraded by equities research analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a report issued on Saturday.

Other research analysts have also recently issued reports about the company. Weiss Ratings restated a “sell (d-)” rating on shares of Avanos Medical in a research note on Monday, December 22nd. Zacks Research upgraded shares of Avanos Medical from a “strong sell” rating to a “hold” rating in a research report on Monday, January 26th. One investment analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Reduce”.

Avanos Medical Price Performance

NYSE:AVNS opened at $13.71 on Friday. The business’s 50-day simple moving average is $13.49 and its two-hundred day simple moving average is $12.27. Avanos Medical has a 52 week low of $9.30 and a 52 week high of $15.68. The stock has a market cap of $637.47 million, a PE ratio of -8.67 and a beta of 1.07. The company has a quick ratio of 1.26, a current ratio of 2.15 and a debt-to-equity ratio of 0.12.

Avanos Medical (NYSE:AVNS) last released its quarterly earnings data on Tuesday, February 24th. The company reported $0.29 earnings per share for the quarter, topping analysts’ consensus estimates of $0.24 by $0.05. Avanos Medical had a positive return on equity of 5.47% and a negative net margin of 10.40%.The firm had revenue of $180.90 million during the quarter, compared to analyst estimates of $174.70 million. During the same quarter in the prior year, the company posted $0.43 earnings per share. The business’s quarterly revenue was up .7% compared to the same quarter last year. Avanos Medical has set its FY 2026 guidance at 0.900-1.100 EPS. As a group, analysts forecast that Avanos Medical will post 1.32 EPS for the current fiscal year.

Institutional Investors Weigh In On Avanos Medical

Several large investors have recently made changes to their positions in AVNS. Corient Private Wealth LLC bought a new position in Avanos Medical during the fourth quarter valued at approximately $234,000. Alpine Global Management LLC bought a new stake in Avanos Medical in the 4th quarter worth approximately $177,000. Vident Advisory LLC bought a new stake in Avanos Medical in the 4th quarter worth approximately $585,000. State of Tennessee Department of Treasury raised its holdings in shares of Avanos Medical by 50.0% during the 4th quarter. State of Tennessee Department of Treasury now owns 41,405 shares of the company’s stock worth $465,000 after acquiring an additional 13,799 shares in the last quarter. Finally, EP Wealth Advisors LLC bought a new position in shares of Avanos Medical during the 4th quarter valued at approximately $201,000. 95.17% of the stock is owned by institutional investors.

About Avanos Medical

Avanos Medical is a global medical technology company that develops and markets a broad portfolio of medical devices intended to improve patient outcomes in hospital, outpatient and post-acute care settings. The company’s products focus on three core therapy areas—pain management, enteral feeding and respiratory care—designed to help clinicians manage post-operative pain, deliver nutrition support and assist breathing for patients across a variety of acute and chronic conditions.

In its pain management segment, Avanos offers both non-opioid drug delivery systems and cryoanalgesia devices, including ambulatory infusion pumps and cooled radiofrequency ablation platforms.